1 Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47–60.9.
2 Francescato M, Cherkaoui A, Merlini L, Schrenzel J, Ceroni D. Osteoartikuläre Kingella kingaella-Infektionen beim Kleinkind. Pediatrica. 2011;22(2):7–8.
3 Mellins ED, Maaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.
Nat Rev Rheumatol. 2011;7: 416–26.
4 Southwood TR, Forster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011;50:189–95.
5 Woerner A., Uettwiller F., Melki I. et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1.
6 Davies HD. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2).
7 Hooper M, Wenkert D, Bitman B et al. Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports. Pediatr Rheumatol Online J. 2013;11(1):35.